Toronto Stock Exchange Symbol: CYT
MONTREAL, April 3 /PRNewswire-FirstCall/ - CryoCath (TSX: CYT), the
global leader in cryotherapy products to treat cardiac arrhythmias, today
announced that data on the Company's Arctic Front(R) catheter system to
treat Atrial Fibrillation (AFib) was presented at the 74th Annual Meeting
of the German Cardiac Society in Mannheim, Germany, March 27-29, 2008.
CryoCath was well represented at the meeting, with a record number of
presentations on cryo-ablation. In total there were eight poster
presentations and ten oral presentations, including a standing room only
cryo symposium from leading electrophysiologists that received 50 percent
more attendance than the previous year.
Some of the highlights of the meeting include:
- Data from a three centre AFib study on Arctic Front by Professor Dr.
Schumacher from Herz- und GefaB-Klinik in Bad Neustadt, Germany,
Dr. Pitschner from the Kerckhoff-Klinik in Bad Nauheim, Germany and
Dr. Vogt from the Herz und Diabetes Zentrum NRW in Bad Oeynhausen,
Germany. With a median follow-up time of 12 months, 74 percent of the
293 paroxysmal patients enrolled were AFib free after only one
procedure and off anti-arrhythmic drugs (AADs).
- Dr. Heintze, also from the Herz und Diabetes Zentrum NRW, presented
follow up data on 168 patients treated in his center. This data
includes patients from the three center AFib study listed above as
well as a significant number of patients treated subsequently. The
group of AFib sufferers was largely paroxysmal with approximately
7 percent persistent. After an average of 8.5 months follow up,
81 percent were AFib free and off drugs and more than 85 percent were
considered a clinical success.
- Data from all presentations collectively determined that with proper
management of the procedure and medical monitoring, the safety
profile of Arctic Front continues to be very strong with no
significant, long-term complications or Major Adverse Cardiac Events
(MACE). Phrenic nerve palsies were largely transient and were
resolved by the end of the procedure or hospital discharge and the
remainder by the 12 month follow up visit.
"This data, in line with previously reported results, bolsters our confidence that Arctic Front is rapidly becoming the standard of care for paroxysmal AFib," said Jan Keltjens, President and CEO of CryoCath. "What is exciting is the consistency these results represent. They are in line with results from our STOP AF IDE feasibility studies and data presented at previous scientific conferences and symposiums. It means Arctic Front is doing what it's supposed to do - provide a simple, anatomical based procedure resulting in safe and consistently efficacious outcomes."
About Arctic Front
Arctic Front is a minimally invasive cryo-balloon catheter designed specifically to treat paroxysmal Atrial Fibrillation. This bi-directional, double balloon catheter enables physicians to rapidly isolate all four pulmonary veins for the treatment of AFib. As of the end of December 2007, an estimated 2100 patients have been treated in 34 centers across Europe since approval.
CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.
This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.
|SOURCE CryoCath Technologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved